Merck & Co Inc (FRA:6MK)
€ 92.9 -0.2 (-0.21%) Market Cap: 236.96 Bil Enterprise Value: 261.27 Bil PE Ratio: 21.36 PB Ratio: 5.93 GF Score: 78/100

Merck & Co Inc at Barclays Global Healthcare Conference Transcript

Mar 12, 2024 / 07:05PM GMT
Release Date Price: €112.6 (+0.54%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Good afternoon and welcome to Day 1 of the Barclays Global Healthcare Conference. My name is Carter Gould, covering U.S. biopharma. I'm pleased to welcome Merck to the stage. Merck is one of our top picks to start the year. And it's been a good year for Merck.

Joining us from the company, Jannie Oosthuizen, President, Human Health U.S.; as well as Peter Griffith (sic) from the IR team. Welcome, Merck. Thank you very much for joining us.

Maybe before we get to start. We can just jump into Q&A. If you want to make some opening comments. But I think we were just going to jump in as we discussed, yes?

Johannes J. Oosthuizen
Merck & Co., Inc. - Senior VP & President Merck U.S. Human Health

Well, I mean, I can just make a few comments. But thank you for having us, Carter. It's good to be back. You said it, I think it's an exciting time to be at Merck. We're benefiting from strong execution across our clinical program, across our commercial organization. And we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot